Startups at the Innovation Competition

Donisi

Free from wearables and wires Donisi is the only clinically validated contact-free technology that can identify increased lung fluid content at home. Our easy-to-use devices are based upon FDA-cleared technology and backed up by 11 granted patents.

Helping to optimize the continuum of care and improve lives for people with CHF and other chronic diseases, Donisi’s in-home health detection and personalized trend analysis enables a pre-emptive approach, fulfilling unmet needs of cardiac and pulmonary health monitoring in the home.
Donisi is the only clinically validated contact-free technology that can identify increased lung fluid content. Our easy-to-use devices are based upon FDA-cleared technology and backed up by 11 granted patents.
Free from wearables and wires, Donisi delivers simultaneous measurement of key bio-parameters, including detection of pulmonary congestion/fluid in the lungs (critical in CHF and other diseases).

Serenus. AI

Serenus.AI (US patent and 4 patents pending) is the first AIbased platform that empowers patients and medical
professionals at critical post-diagnostic crossroads on
patient pathways, saving lives and valuable resources. Our
flagship product is the first clinically objective, AI-based,
automated case-by-case review system to improve
decision-making before medical procedures. Serenus.AI
advances the quality of care, saves valuable resources and
boosts patients’, physicians’ and payers’ satisfaction across
the board.

Healables

Healables.io is a digital health startup with an AI-driven behavioral health coach and
wearable digital therapeutic electroceutical device that docks with smart textiles for
the home-based and remote treatment of sports injuries, chronic illness & chronic
pain. We accelerate healing, reduce inflammation and relieve pain.

Covellus

Covellus’ patented Modular Catheter Architecture is a new design and use paradigm for
endovascular and other minimally invasive surgical device catheters. Our first product is
the Modular Balloon System, which uses conventional .035 PTA balloons to let physicians
build all the Balloon Catheter Solutions they would typically need in peripheral
endovascular procedures plus Balloon Solutions not available through conventional
designs… all at the point of care. The Modular Balloon System can create Balloon Catheter
Solutions adaptable to any Cath Lab operations, with customization options for a
physicians practice and procedures. It is a dramatic shift from the undifferentiated PTA
balloon products available today.

CardioBra

CardioBra is a patent-pending medical garment designed for exercise stress testing in women. Cardiobra limits breast motion, promotes accurate ECG lead placement, reduces ECG lead artifact and ECG lead adherence, allows rapid access for echocardiogram image acquisition, and limits artifact in nuclear stress testing. CardioBra improves patient comfort and satisfaction by supporting breast tissue and only exposing the breast in areas where needed for the exam.

TEEB

TEEB is a healthtech startup that builds decentralized infrastructure in order to provide Accessible and Universal healthcare for all.

VOTIS

Peripheral artery disease, or PAD, is one of the most common vascular complications of diabetes, affecting 1 in 3 diabetics over the age of 50 and 200M people worldwide. When a diabetic foot ulcer emerges, it may be too late to do anything but amputate. VOTIS is developing a suite of non-invasive, fast, safe, accurate, and affordable devices to evaluate blood flow and oxygenation in specific locations in the foot. The devices use Hemodynamic Occlusive Vascular Response (HOVR™) technology, based on non-ionizing radiation: patches containing photodetectors measure light scattering and absorption to determine blood flow and oxygen levels in the foot. The test takes just 5 minutes and reaches a depth of up to 2 cm. With the VOTIS devices, for the first time, doctors can properly see what they are doing: “You can’t treat what you can’t measure.” Early detection saves money, limbs, and lives.

A.N.T

“A.N.T. delivers Sirolimus boosted by Paclitaxel on a DCB while leaving nothing behind in the body. Increased potency and effectiveness can be accomplished by co-locating Paclitaxel and Sirolimus in the same nanoparticle, thereby leveraging its synergistic effect to inhibit cellular growth while maintaining drug safety. Although a common pharmacological practice, A.N.T’s proprietary nanotechnology platform for medical devices is the only therapeutic option able to safely and reliably deliver dual-pharmacology agents during cardiovascular and endovascular minimally invasive surgical interventions. A.N.T.’s platform nanoparticle technology has applications across multiple large addressable markets, including cardiovascular, endovascular, neurovascular, orthopedic, ophthalmic, and pain. However, A.N.T.’s dual-drug DCB will initially address the immediate unmet need for cardiovascular and endovascular applications. The first market opportunity is in peripheral artery disease to address the critical limb ischemia patient population, which currently has no sustainable clinical solution.  A.N.T. is also actively working on a dual-drug DCB for coronary application, including In-Stent Restenosis, Small Coronary Vessel, and de-novo lesions.” Our website is www.advancednanotherapies.com

Alio Medical

Alio Medical is an early-stage, advanced medical technology company with the Alio Monitoring System, which provides continuous, remote, noninvasive monitoring of end stage renal disease patients undergoing hemodialysis. Alio monitors dialysis patient blood flow by capturing and transmitting multimodal sensor data at regular intervals using quantitative analysis of optical, mechanical, acoustic, and thermal data related to blood flow and the composition of the blood itself.

The Alio Monitoring System utilizes a wearable device, the SmartPatch, placed over the patient’s vascular access graft to gather data and transmit it to a Hub located in the patient’s home. The Hub relays this raw data to the Alio Cloud where it is processed and analyzed utilizing Alio’s proprietary algorithms, developed using data collected pre- and post-dialysis in clinical centers in the US and UK. This clinically actionable data is accessed by the clinical team via a web-based data portal or the electronic health record, and the clinical team is alerted if an abnormality in a patient’s serum potassium is detected.

MARCH

Here is the link to our website and LinkedIn.
March: AI-powered Women’s Health Assistant for Menstrual Wellness (App and Wearable)
The following is a brief bio of the March’s founder:
“Engineer and serial entrepreneur leading his 3rd business after two successful exits, Mark has 14 years of experience in building products and scaling businesses. He is the author of a top-seller award-winning engineering book. Mark is the founder and CEO of March Health, a startup company that has developed an AI-powered women’s health assistant (App and Wearable) to ease physical and mental menstrual discomforts. Two years ago, Mark and his wife lost a baby due to endometriosis complications. He ended up developing this wearable and app in order to primarily help his wife who has long suffered from excruciating menstrual pain, and his product

was practical enough to see a huge global market, thus he began this journey with the team and co-founders to scale the business into a global business.”

INVATIN

developed the SYNAXIS, a first in class permanent aortic implantable apparatus for diversion of thromboembolic materials away from the brain. The device was developed to address the large population of patients with atrial fibrillation (AF), high stroke risk, and high bleeding risk. Patients that cannot be treated with other measures are the ultimate candidates for the SYNAXIS. Accordingly, it may be used in patients with intra-cardiac thrombi and in patients who are at risk for non-LAA related cerebral embolization. The device confers a new approach towards stroke prevention, and hold several advantages as compared with available technologies and drugs. For more information please see: Company Web site : www.invatin.com Synaxis introduction video : https://www.youtube.com/watch?v=d8wckBvxbz4 Or contact : info@invatin.com

Nininger Medical

Our vision is to give patients heart valves that last a lifetime without requiring repeat interventions or replacement. Nininger Medical will replace failing tricuspid valves using new 3D thin-film technology. Nitinol film ten times thinner than the material currently used in most heart valve devices will allow our device to be crimped into a smaller catheter, thereby enabling delivery in even the most challenging anatomy. The film provides increased durability and significantly reduced manufacturing cost compared to pericardial tissue valves.

Intratech

Intratech is developing the Booster™ spiral balloon for the semi-occlusion of the coronary sinus, to improve the efficacy of coronary intervention for AMI patients. Around 16 million people worldwide have a heart attack every year. Up to 30% of patients with acute myocardial infarction (AMI) will develop heart failure which has a huge impact on overall health and patient quality of life. After the revascularization of the clogged artery, the Booster™ balloon is placed in the coronary sinus vein, and due to its unique spiral design, it increases vascular pressure. This elevated pressure enhances blood perfusion into the affected myocardium, improving the patient’s cardiac function. Intratech has promising pre-clinical results and is about to start its First-In-Human clinical trial in 2021. The company has secured a major investment from a key strategic corporation in the interventional cardiology field and has a comprehensive patent family with patents granted globally.

Coramaze

Coramaze Technologies develops a treatment for functional Tricuspid Regurgitation (fTR) in heart failure patients, to improve quality of life and reduce morbidity. The Tripair implant is based on spacer coaptation technology and anchored a-traumatically in the right atrium, enabling full retrievability and intra-procedural efficacy evaluation.

Voxi

Voxi products are digitizing the speech therapy processes in order to positively impact children with speech impairments and reduce recovery time, thus helping them better integrate into their social environment and school community.
We started with VoxiKids, a mobile app presented as an example of a digital product for the e-health sector as it will also use Speech Recognition for special therapy exercises.
During the pandemic, we realized the need for an online platform dedicated to speech therapists. That’s why we launched in January 2021 VoxiClinic, the first digital clinic dedicated to speech. We’re bringing a SaaS platform to the e-health market, offering a selection of high-value materials designed by speech pathologists, as well as management tools that streamline the collaboration between parent and therapist, with the common goal of assisting the child’s recovery, thus enabling parents to connect from anywhere in the world to the speech therapist they need.

Powerful Medical

Powerful Medical is a deep-tech company, developing life-saving technology and tackling one of the biggest challenges of modern medicine – cardiovascular diseases. Cardiovascular diseases are the number one cause of death worldwide and 9 out of 10 ECGs are not interpreted by a specialized cardiologist. Therefore, we developed an AI-clinical assistant which allows any physician to interpret an ECG like a cardiologist with 15 years of experience.

The development of our clinical products is done by our international team of 60+ experienced entrepreneurs, physicians, AI experts, sales and marketing, engineers, data scientists, regulatory experts, and developers making breakthrough clinical advancements using deep tech – thus combining solid business fundamentals with cutting-edge technology and the latest clinical research. 

Our clinical efforts are guided by an experienced Scientific Board with decades of medical experience – including both research and day-to-day clinical practice.  Members of our Scientific Board include Dr. Jozef Bartunek, PhD, who is Associate Director of the Cardiovascular Center in Aalst, Belgium, or Prof. Dr. Robert Hatala, PhD – Head of Cardiology at the National Institute of Cardiovascular Diseases in Slovakia. The Chairman of our Scientific Board is Dr. Leor Perl, Director of the Innovation Laboratory at the Rabin Medical Center in Israel

UltraSight

UltraSight aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. The UltraSight automated guidance system and advanced usability features help bring the benefits of cardiac imaging to more healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. In 2020, UltraSight won the TCT Innovation Competition, which took place during the Transcatheter Cardiovascular Therapeutics world conference. For more news and information, visit our website or follow UltraSight on LinkedIn and Twitter.

GlyCardial

GlyCardial Diagnostics has developed an accurate and proprietary biomarker for the early detection of cardiac ischemia using a simple blood test.

The technology is based on the detection of glycosylated Apolipoprotein J (ApoJ-Glyc) in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patients’ evolution after an ischemic event.